Innovation Pharmaceuticals Stock Return On Asset
| IPIX Stock | USD 0.0003 0.0002 200.00% |
Innovation Pharmaceuticals fundamentals help investors to digest information that contributes to Innovation Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Innovation Pink Sheet. The fundamental analysis module provides a way to measure Innovation Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Innovation Pharmaceuticals pink sheet.
Innovation |
Innovation Pharmaceuticals Company Return On Asset Analysis
Innovation Pharmaceuticals' Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.
Current Innovation Pharmaceuticals Return On Asset | -0.32 |
Most of Innovation Pharmaceuticals' fundamental indicators, such as Return On Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Innovation Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Return on Asset measures overall efficiency of a company in generating profits from its total assets. It is expressed as the percentage of profits earned per dollar of Asset. A low ROA typically means that a company is asset-intensive and therefore will needs more money to continue generating revenue in the future.
| Competition |
Based on the latest financial disclosure, Innovation Pharmaceuticals has a Return On Asset of -0.3177. This is 96.37% lower than that of the Biotechnology sector and 98.65% lower than that of the Health Care industry. The return on asset for all United States stocks is 126.93% higher than that of the company.
Innovation Return On Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Innovation Pharmaceuticals' direct or indirect competition against its Return On Asset to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Innovation Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Innovation Pharmaceuticals by comparing valuation metrics of similar companies.Innovation Pharmaceuticals is currently under evaluation in return on asset category among its peers.
Innovation Fundamentals
| Return On Equity | -1.09 | |||
| Return On Asset | -0.32 | |||
| Operating Margin | (339.83) % | |||
| Current Valuation | 7.56 M | |||
| Shares Outstanding | 488.32 M | |||
| Shares Owned By Insiders | 10.10 % | |||
| Price To Earning | (7.57) X | |||
| Price To Book | 2.95 X | |||
| Price To Sales | 557.16 X | |||
| Revenue | 18 K | |||
| Gross Profit | 18 K | |||
| EBITDA | (6.54 M) | |||
| Net Income | (7.04 M) | |||
| Cash And Equivalents | 2.97 M | |||
| Cash Per Share | 0.01 X | |||
| Total Debt | 1.24 M | |||
| Debt To Equity | 0.36 % | |||
| Current Ratio | 0.60 X | |||
| Book Value Per Share | 0.01 X | |||
| Cash Flow From Operations | (6.28 M) | |||
| Earnings Per Share | (0.02) X | |||
| Beta | 0.18 | |||
| Market Capitalization | 9.52 M | |||
| Total Asset | 10.38 M | |||
| Retained Earnings | (87.38 M) | |||
| Working Capital | 44.72 K | |||
| Current Asset | 529.15 K | |||
| Current Liabilities | 484.43 K | |||
| Z Score | -7.0 | |||
| Net Asset | 10.38 M |
About Innovation Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Innovation Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Innovation Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Innovation Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Innovation Pink Sheet Analysis
When running Innovation Pharmaceuticals' price analysis, check to measure Innovation Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Innovation Pharmaceuticals is operating at the current time. Most of Innovation Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Innovation Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Innovation Pharmaceuticals' price. Additionally, you may evaluate how the addition of Innovation Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.